Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Insite Vision Inc. (AMEX:ISV)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider | Financials
Recent Events
Aug  9Earnings Announcement
Location
965 Atlantic Avenue
Alameda, CA 94501
Phone: (510) 865-8800
Fax: (510) 865-5700
Email: insitemail@insite.com
Employees (last reported count): 37
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 16%
·Over the last 6 months:
 · 2 insider buys; 20.0K shares (0.5% of insider shares)
·Institutional: 16% (19% of float)
(24 institutions)
·Net Inst. Selling: 926.0K shares (+31.20%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Insite Vision Incorporated is an ophthalmic product development company focused on developing genetically based tools for the diagnosis, prognosis and management of glaucoma, as well as ophthalmic pharmaceutical products based on its proprietary DuraSite eyedrop-based drug delivery technology. The Company's retinal programs include both therapeutic agents and drug delivery technologies. The Company is focusing its research and development on expanding its ISV-900 technology for the diagnosis, prognosis and management of glaucoma. It is also focused on ISV-205, a DuraSite formulation for the treatment of glaucoma; ISV-401, a DuraSite formulation of a novel antibiotic not used in ophthalmology; ISV-403, a DuraSite formulation of a second-generation fluoroquinolone; ISV-014, a retinal drug delivery device, and treatments for diabetic retinopathy and macular degeneration.
More from Market Guide: Expanded Business Description

Financial Summary
Insite Vision, Inc. is engaged in the development of ophthalmic drugs and ophthalmic drug delivery systems, utilizing a glaucoma genetics program, the DuraSite delivery system, and a retinal delivery system. For the six months ended 6/30/01, revenues totalled $3 thousand, down from $800 thousand. Net loss applicable to Common before accounting change totalled $4.3 million, up from $590 thousand. Results reflect the absence of license fees, and increased research and development expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

S. Kumar Chandrasekaran, Ph.D., 58
Chairman, Pres, CEO and Chief Financial Officer
$355K$399K
Lyle Bowman, Ph.D., 52
VP of Devel. and Operations
196K116K
Cheryl Chen, 41
Sr. Director, Clinical Operations
--  --  
T. Raymond Chen, Ph.D., 50
Sr. Director, Regulatory, Quality Assurance and Quality Control
--  --  
Sandra Heine, 39
Sr. Director, Fin. and Admin.
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:ISVAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-May-2001
$0.90 
Recent Price$1.28 
52-Week High
on 5-Oct-2000
$8.50 
Beta1.12 
Daily Volume (3-month avg)41.2K
Daily Volume (10-day avg)20.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-81.6%
52-Week Change
relative to S&P500
-75.2%
Share-Related Items
Market Capitalization$31.9M
Shares Outstanding24.9M
Float20.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.58 
Earnings (ttm)-$0.10 
Earnings (mrq)-$0.09 
Sales (ttm)$0.17 
Cash (mrq)$0.58 
Valuation Ratios
Price/Book (mrq)2.19 
Price/EarningsN/A 
Price/Sales (ttm)7.31 
Income Statements
Sales (ttm)$4.51M
EBITDA (ttm)-$2.48M
Income available to common (ttm)-$1.90M
Profitability
Profit Margin (ttm)-42.1%
Operating Margin (ttm)-63.0%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-9.61%
Return on Equity (ttm)-10.49%
Financial Strength
Current Ratio (mrq)11.39 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$14.5M
Short Interest
As of 8-Aug-2001
Shares Short0 
Shares Short
(Prior Month)
0 
Daily Volume20.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.